Five-Alpha Reductase Inhibitor and Breast Cancer Risk in Men: A Systematic Review

    January 2017 in “ Annals of Dermatology ”
    Min Woo Kim, Hyun Sun Park, Jong Seo Park … Soyun Cho
    Studysummary Taking 5-alpha reductase inhibitors does not increase breast cancer risk in men.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on europepmc.org →
    Discuss this study in the Community →

    Research cited in this study 6

    1. Long-Term Use of 5α-Reductase Inhibitors and the Risk of Male Breast Cancer Cancer Causes & Control · 2014
    2. Male Breast Cancer and 5α-Reductase Inhibitors Finasteride and Dutasteride The Journal of Urology · 2013
    3. Finasteride and Male Breast Cancer: Does the MHRA Report Show a Link? PubMed · 2010
    4. The Effect of 5α-Reductase Inhibition with Dutasteride and Finasteride on Semen Parameters and Serum Hormones in Healthy Men The Journal of Clinical Endocrinology and Metabolism · 2007
    5. The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia The New England Journal of Medicine · 2003
    6. The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment Among Men with Benign Prostatic Hyperplasia The New England Journal of Medicine · 1998